西黄胶囊联合化疗治疗肺癌-降低血管内皮生长因子随机平行对照研究

目的]观察西黄胶囊联合化疗治疗肺癌-降低血管内皮生长因子疗效。方法]使用随机平行对照方法,将72例住院患者按病志号抽签简单随机分为两组。对照组36例按耐药性及药敏反应试验情况选择方案:①DP:多西他赛75mg/m2·次,第1d静滴;顺铂75mg/m2·次,分3d静滴;②GP:吉西他滨1.0g/m2·次,第1、8d静滴;顺铂75mg/m2·次,3d静滴。治疗组36例西黄胶囊,1~2g/次,2次/d,口服;西医治疗同对照组。连续治疗42d为1疗程。观测临床症状、血管内皮生长因子(VEGF)、不良反应。治疗1疗程,判定疗效。结果]治疗组完全缓解0例,部分缓解18例,病情稳定11例,疾病进展7例,总有效率80.55%。对照组完全缓解0例,部分缓解11例,病情稳定12例,疾病进展13例,总有效率63.88%。治疗组疗效优于对照组(P0.05)。血清VEGF浓度两组均有下降(P0.05),治疗组下降幅度大于对照组(P0.05)。不同临床疗效中血清VEGF浓度均有下降(P0.05),各临床疗效中治疗组下降幅度均大于对照组(P0.05)结论]西黄胶囊联合化疗治疗肺癌效果满意,可明显降低血清血管内皮生长因子,值得推广。

Factor and Efficacy Randomized Controlled Study in Parallel the Growth of Western Intervention in the West Yellow Capsule Combined with Chemotherapy in Patients with Lung Cancer Serum Vascular Endothelial

Objective ] To observe the yellow capsule combined with Western intervention in West serum vascular endothelial growth factor in lung cancer patients treated with chemotherapy and efficacy of treatment. Methods ] Random parallel control method, 72 cases of hospitalized patients were randomly divided into two groups. A control group of 36 patients by patient resistance and susceptibility reaction test case options. （1） simple DP. Docetaxel, 75mg / times, the first ld infusion;cisplatin, 75mg / times, 1 times / d, the first 1 3d infusion. （2） GP. Gemcitabine, 1.0g / times, the first 1 - 8d infusion; eisplatin, 75mg / times, 1 times / d, 1 - 3d infusion. Western intervention group 36 cases of yellow capsules, 1 - 2g / times, 2 times / d, orally. Western medicine with the control group. 42d is a continuous treatment intervention. Observation of clinical symptoms, adverse reactions, serum VEGF concentration, a continuous course of treatment interventions to determine efficacy. Results ] In the intervention group partial remission in 18 cases, 11 cases of stable disease, progressive disease in 7 cases, the total efficiency of 80.55%. Partial remission in 11 cases in the control group, 12 cases of stable disease, progressive disease in 13 cases, the total efficiency of 63.88%. The efficacy of the intervention group than the control group （ P〈0.05 ） . Serum VEGF levels were improved in both groups （ P 〈0.05 ）, improvement in the intervention group than the control group （ P 〈0.05 ） . Two different serum VEGF levels were decreased efficacy in patients （P〈0.05）, a decrease in the intervention group than the control group （ P 〈0.05 ） . Conclusion ] West yellow capsule combined with Western medicine intervention serum vascular endothelial growth factor in lung cancer patients treated with chemotherapy and efficacy results are obvious, it is worth promoting.